Gilead Sciences (NASDAQ:GILD) Given New $95.00 Price Target at Barclays

Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective raised by Barclays from $84.00 to $95.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. Sanford C. Bernstein started coverage on […]

Leave a Reply

Your email address will not be published.

Previous post Allstate (NYSE:ALL) Price Target Raised to $228.00 at Morgan Stanley
Next post Piper Sandler Issues Pessimistic Forecast for Rapid7 (NASDAQ:RPD) Stock Price